L. Robinson

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

J. Byrne, M. Copland, R. Clark, 2019, The Lancet. Haematology.

Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study

J. Byrne, M. Copland, R. Clark, 2019 .

Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study.

I. Sutton, J. Eisenhoffer, M. Csanádi, 2013, Pain research & management.

Inotrope versus Placebo Therapy in Cardiogenic Shock: Rationale and Study Design of the CAPITAL DOREMI2 Trial.

S. Fernando, E. Belley‐Cote, G. Wells, 2023, American heart journal.